Developer docs
API playgroundTry for free, no card

Search company profiles

Cyclacel Pharmaceuticals

Full company profile

uuid0004zmj

Namestring
Cyclacel Pharmaceuticals
Legal namestring
Bio Green Med Solution, Inc.
Websiteurl
cyclacel.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a publicly traded clinical-stage biopharmaceutical company developing oral therapies for cancers and other critical diseases based on cancer cell cycle biology, epigenetics, and mitosis biology. The company's lead product candidate is Plogosertib (CYC140), a proprietary PLK1 inhibitor being developed for esophageal cancer and acute leukemia, with peer-reviewed therapeutic potential presented at AACR (April 2017) and EORTC-NCI-AACR (December 2016). The company has historically operated with no approved products and no commercial product revenue, instead relying on recurring dilutive financings — including a $1.3 million registered direct offering in December 2023, an $8.0 million private placement in April-May 2024, a $2.1 million raise in November 2024, a $1.0 million raise in March 2025, and a $3.0 million convertible preferred placement in June 2025 — to extend cash runway.

In May 2025, the company executed a Share Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysia-based fire protection products and services company established in 1982. Following the expected August 2025 close, Cyclacel rebranded as Bio Green Med Solution, Inc., repositioning itself as a diversified holding company with operational headquarters in Kuala Lumpur, Malaysia. Post-transaction, legacy Cyclacel stockholders own approximately 80% of the combined entity. The consolidated company now operates two segments: a fire safety division (fire equipment, foam systems, fire-resistant doors, PPE, safety apparel) and a biopharmaceutical division anchored on Plogosertib. Leadership includes Paul McBarron as Executive Vice President, CFO and COO (a director since 2006), and the company has announced a further acquisition of Future NRG for June 2026, signaling continued inorganic diversification.

Short descriptiontext

Bio Green Med Solution (formerly Cyclacel Pharmaceuticals) is a clinical-stage biopharmaceutical company developing cancer therapies based on cell cycle biology, now diversified into fire protection products through its acquisition of Malaysia-based Fitters Sdn. Bhd.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDundee, United Kingdom
HQ citystring
Dundee
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, cancer cell cycle biology, PLK1 inhibitor therapy, fire safety equipment, oncology drug development
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Biopharmaceuticals
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology, with lead candidate Plogosertib (CYC140), a novel PLK1 inhibitor for esophageal cancer and acute leukemia. Following the 2025 acquisition of Fitters Sdn. Bhd., the company also supplies fire protection products and services including fire equipment, foam systems, fire resistant doors, and personal protective equipment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The company operates as a pioneer in cancer cell cycle biology, with its primary product candidate being Plogosertib, a PLK1 inhibitor targeting cancer cell division pathways. The company has also expanded into fire safety products through its acquisition of Fitters Sdn. Bhd., creating a diversified portfolio spanning oncology and industrial safety sectors.

Product and service1 record
1Plogosertib (CYC140)
CategoryOncology drug candidate
Description

A novel PLK1 inhibitor drug candidate being developed by Cyclacel/Bio Green Med Solution for the treatment of esophageal cancer and acute leukemia, with potential applications across multiple cancer indications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-06
Description

Cyclacel Pharmaceuticals entered into a Share Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary Fitters Sdn. Bhd. as a wholly-owned subsidiary. The transaction, expected to close by August 2025, involves Cyclacel issuing stock to FITTERS, with Cyclacel stockholders owning approximately 80% of the combined entity post-transaction.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Calithera Biosciences
TypeDirect peer
Description

Calithera develops small-molecule oncology drugs targeting tumor metabolism and immune regulation; comparable as a small-cap clinical-stage oncology developer that has navigated financing-driven dilution similar to BGMS.

2Tragara Pharmaceuticals
TypeDirect peer
Description

Tragara is a clinical-stage oncology company whose lead program (capmatinib/HGF/MET axis and earlier PLK1 work) and overall positioning as a small-cap cancer therapeutics developer make it closely comparable to BGMS's Plogosertib PLK1 program.

TypeDirect peer
Description

Aprea is a clinical-stage oncology company focused on small-molecule cancer therapies; its micro-cap public status and early-to-mid-stage pipeline parallel BGMS's clinical positioning with Plogosertib.

4DelMar Pharmaceuticals
TypeDirect peer
Description

DelMar is a clinical-stage oncology developer focused on novel cancer therapies; it matches BGMS on size, listing profile, and dependence on capital markets to advance a single clinical-stage oncology asset.

5Onconova Therapeutics
TypeDirect peer
Description

Onconova is a clinical-stage biopharmaceutical company developing small-molecule oncology candidates (e.g., rigosertib) — a near-identical micro-cap clinical-oncology profile to BGMS in scale, modality and stage.

TypeDirect peer
Description

BioXcel is a clinical-stage biopharmaceutical company developing small-molecule therapies in oncology and neuroscience; comparable as a small-cap, publicly listed, clinical-stage developer with multiple shots on goal.

7Mateon Therapeutics
TypeDirect peer
Description

Mateon is a clinical-stage immuno-oncology / small-molecule developer; it is a comparable micro-cap public peer with a similarly narrow clinical pipeline and ongoing financing needs.

TypeDirect peer
Description

Genprex is a clinical-stage oncology company developing gene- and small-molecule-based cancer therapies; it is comparable to BGMS as a micro-cap, publicly listed, clinical-stage oncology developer dependent on periodic equity raises.

9Rigel Pharmaceuticals
TypeDirect peer
Description

Rigel develops small-molecule drugs in oncology and hematology, including cell-cycle-adjacent targets; as a small-cap commercial-stage oncology peer it shares BGMS's target-class focus and clinical-stage commercialization trajectory.

10Nerviano Medical Sciences
TypeEmerging player
Description

Nerviano is an oncology-focused discovery and development company with deep expertise in cell-cycle and kinase targets (including PLK inhibitors such as volasertib); it is comparable as an emerging player in the same PLK1 / cell-cycle chemistry space that underpins Plogosertib.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyclacel Pharmaceuticals

Clinical-Stage Oncology Biopharmaceuticalscyclacel.com

Bio Green Med Solution (formerly Cyclacel Pharmaceuticals) is a clinical-stage biopharmaceutical company developing cancer therapies based on cell cycle biology, now diversified into fire protection products through its acquisition of Malaysia-based Fitters Sdn. Bhd.

What Cyclacel Pharmaceuticals does

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a publicly traded clinical-stage biopharmaceutical company developing oral therapies for cancers and other critical diseases based on cancer cell cycle biology, epigenetics, and mitosis biology. The company's lead product candidate is Plogosertib (CYC140), a proprietary PLK1 inhibitor being developed for esophageal cancer and acute leukemia, with peer-reviewed therapeutic potential presented at AACR (April 2017) and EORTC-NCI-AACR (December 2016). The company has historically operated with no approved products and no commercial product revenue, instead relying on recurring dilutive financings — including a $1.3 million registered direct offering in December 2023, an $8.0 million private placement in April-May 2024, a $2.1 million raise in November 2024, a $1.0 million raise in March 2025, and a $3.0 million convertible preferred placement in June 2025 — to extend cash runway.

In May 2025, the company executed a Share Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysia-based fire protection products and services company established in 1982. Following the expected August 2025 close, Cyclacel rebranded as Bio Green Med Solution, Inc., repositioning itself as a diversified holding company with operational headquarters in Kuala Lumpur, Malaysia. Post-transaction, legacy Cyclacel stockholders own approximately 80% of the combined entity. The consolidated company now operates two segments: a fire safety division (fire equipment, foam systems, fire-resistant doors, PPE, safety apparel) and a biopharmaceutical division anchored on Plogosertib. Leadership includes Paul McBarron as Executive Vice President, CFO and COO (a director since 2006), and the company has announced a further acquisition of Future NRG for June 2026, signaling continued inorganic diversification.

Cyclacel Pharmaceuticals firmographics

Firmographics
Name
Cyclacel Pharmaceuticals
Legal name
Bio Green Med Solution, Inc.
Website
https://cyclacel.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
Bio Green Med Solution (formerly Cyclacel Pharmaceuticals) is a clinical-stage biopharmaceutical company developing cancer therapies based on cell cycle biology, now diversified into fire protection products through its acquisition of Malaysia-based Fitters Sdn. Bhd.
Ownership category
akta.pro rank

Where Cyclacel Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Dundee
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Cyclacel Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Others

Marketing channels3 records

Cyclacel Pharmaceuticals product offering

Product offering

Core offering

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology, with lead candidate Plogosertib (CYC140), a novel PLK1 inhibitor for esophageal cancer and acute leukemia. Following the 2025 acquisition of Fitters Sdn. Bhd., the company also supplies fire protection products and services including fire equipment, foam systems, fire resistant doors, and personal protective equipment.

Product overview

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The company operates as a pioneer in cancer cell cycle biology, with its primary product candidate being Plogosertib, a PLK1 inhibitor targeting cancer cell division pathways. The company has also expanded into fire safety products through its acquisition of Fitters Sdn. Bhd., creating a diversified portfolio spanning oncology and industrial safety sectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plogosertib (CYC140) A novel PLK1 inhibitor drug candidate being developed by Cyclacel/Bio Green Med Solution for the treatment of esophageal cancer and acute leukemia, with potential applications across multiple cancer indications.

Companies that use Cyclacel Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Cyclacel Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cyclacel Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • FITTERS Diversified BerhadcoreStrategic or Co-development Partner · 6 May 2025Cyclacel Pharmaceuticals entered into a Share Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary Fitters Sdn. Bhd. as a wholly-owned subsidiary. The transaction, expected to close by August 2025, involves Cyclacel issuing stock to FITTERS, with Cyclacel stockholders owning approximately 80% of the combined entity post-transaction.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Cyclacel Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Calithera Biosciences: Calithera develops small-molecule oncology drugs targeting tumor metabolism and immune regulation; comparable as a small-cap clinical-stage oncology developer that has navigated financing-driven dilution similar to BGMS.
  • Tragara Pharmaceuticals: Tragara is a clinical-stage oncology company whose lead program (capmatinib/HGF/MET axis and earlier PLK1 work) and overall positioning as a small-cap cancer therapeutics developer make it closely comparable to BGMS's Plogosertib PLK1 program.
  • Aprea Therapeutics: Aprea is a clinical-stage oncology company focused on small-molecule cancer therapies; its micro-cap public status and early-to-mid-stage pipeline parallel BGMS's clinical positioning with Plogosertib.
  • DelMar Pharmaceuticals: DelMar is a clinical-stage oncology developer focused on novel cancer therapies; it matches BGMS on size, listing profile, and dependence on capital markets to advance a single clinical-stage oncology asset.
  • Onconova Therapeutics: Onconova is a clinical-stage biopharmaceutical company developing small-molecule oncology candidates (e.g., rigosertib) — a near-identical micro-cap clinical-oncology profile to BGMS in scale, modality and stage.
  • BioXcel Therapeutics: BioXcel is a clinical-stage biopharmaceutical company developing small-molecule therapies in oncology and neuroscience; comparable as a small-cap, publicly listed, clinical-stage developer with multiple shots on goal.
  • Mateon Therapeutics: Mateon is a clinical-stage immuno-oncology / small-molecule developer; it is a comparable micro-cap public peer with a similarly narrow clinical pipeline and ongoing financing needs.
  • Genprex: Genprex is a clinical-stage oncology company developing gene- and small-molecule-based cancer therapies; it is comparable to BGMS as a micro-cap, publicly listed, clinical-stage oncology developer dependent on periodic equity raises.
  • Rigel Pharmaceuticals: Rigel develops small-molecule drugs in oncology and hematology, including cell-cycle-adjacent targets; as a small-cap commercial-stage oncology peer it shares BGMS's target-class focus and clinical-stage commercialization trajectory.

Emerging players

  • Nerviano Medical Sciences: Nerviano is an oncology-focused discovery and development company with deep expertise in cell-cycle and kinase targets (including PLK inhibitors such as volasertib); it is comparable as an emerging player in the same PLK1 / cell-cycle chemistry space that underpins Plogosertib.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cyclacel Pharmaceuticals social profiles

Digital presence

Cyclacel Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyclacel Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Cyclacel Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cyclacel Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyclacel Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyclacel Pharmaceuticals

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology, with lead candidate Plogosertib (CYC140), a novel PLK1 inhibitor for esophageal cancer and acute leukemia. Following the 2025 acquisition of Fitters Sdn. Bhd., the company also supplies fire protection products and services including fire equipment, foam systems, fire resistant doors, and personal protective equipment.

Is Cyclacel Pharmaceuticals a public or private company?

Cyclacel Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Cyclacel Pharmaceuticals founded?

Cyclacel Pharmaceuticals was founded in 2002. It employs 1 to 10 people.

Where is Cyclacel Pharmaceuticals based?

Cyclacel Pharmaceuticals is headquartered in Dundee, United Kingdom, in the Europe region.

Who are Cyclacel Pharmaceuticals's main competitors?

Direct peers on record are Calithera Biosciences, Tragara Pharmaceuticals, Aprea Therapeutics, DelMar Pharmaceuticals, Onconova Therapeutics, BioXcel Therapeutics, Mateon Therapeutics, Genprex and Rigel Pharmaceuticals. Nerviano Medical Sciences is listed as an emerging player.

Does Cyclacel Pharmaceuticals have an API?

No public API is recorded for Cyclacel Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailyContrasting Xometry (NASDAQ:XMTR) & Cyclacel Pharmaceuticals (NASDAQ:BGMS)MarketBeat published a comparative analysis of Xometry and Cyclacel Pharmaceuticals, evaluating their financial metrics including profitability, valuation, and institutional ownership. The report concluded that Xometry is the superior business, beating Cyclacel on 11 of 14 compared factors, despite both companies currently operating with negative earnings.Quiver QuantitativeBio Green Med Reports $336,000 Second-Quarter Revenue | CYCCP Stock NewsBio Green Med Solution reported second-quarter 2026 revenue of $336,000 from fire safety equipment sales and a net loss of $405,000, while announcing a planned business combination with Future NRG Sdn. Bhd. The company reduced its general and administrative expenses significantly compared to the prior year and holds $3.8 million in cash equivalents. Additionally, BGMS entered a securities purchase agreement expected to yield approximately $794,000 in gross proceeds.MorningstarAre FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating Forte Biosciences, Arcosa, and Bio Green Med Solution for potential securities law violations and fiduciary breaches. The firm may seek increased consideration, additional disclosures, or other relief on a contingent fee basis.Benzinga12 Health Care Stocks Moving In Friday's Pre-Market Session - Aditxt Inc Ordinary Shares (NASDAQ:ADTX), BThis article lists multiple healthcare stocks experiencing significant price movements during Friday's pre-market session, including gains for Bio Green Med Solution and BioCardia, and losses for Cypherpunk Technologies and Indaptus Therapeutics. The report provides specific percentage changes and market capitalization figures for these companies without explaining the underlying reasons for the volatility. Published by Benzinga, the content serves as a routine financial data summary rather than an analysis of corporate events.FutunnBio Green Med Solutions Shares Soar on Acquisition of Future NRGBio Green Med Solutions shares rose following the acquisition of Future NRG. The article also reports that Unity Software's fourth-quarter revenue increased 35% year-over-year to $609 million, beating consensus estimates. Information from Dow Jones is currently unavailable due to copyright issues.Stock TitanBio Green Med 2025 net loss narrows to $3.0MBio Green Med Solution, Inc. reported fourth quarter and full year 2025 financial results, with its net loss narrowing significantly to $3.0 million from $11.2 million in the prior year. The company completed a strategic pivot during 2025, acquiring Fitters Sdn. Bhd., a Malaysia-based fire safety equipment company, on September 12, 2025, while simultaneously liquidating its UK biopharma subsidiary and selling its Plogosertib drug assets. As of December 31, 2025, the company held $3.5 million in cash, which it estimates will fund operations into the third quarter of 2026.Benzinga12 Health Care Stocks Moving In Friday's After-Market Session - Bio Green Med Solution (NASDAQ:BGMS), EstSeveral healthcare stocks experienced significant price changes in Friday's after-market session, with Tivic Health Systems gaining 6.0% and TuHURA Biosciences declining 12.6%. Bio Green Med Solution's shares fell by 7.94%, resulting in a market value of $4.0 million. The article highlights the fluctuations in stock prices for various health care companies during this trading period.TradingViewBio Green Med Solution, Inc. SEC 10-Q ReportBio Green Med Solution, Inc. released its third quarter 2025 Form 10-Q report, detailing a strategic shift from biopharmaceuticals to fire safety protection following the acquisition of Malaysia-based Fitters Sdn. Bhd. The company reported $81,000 in revenue and a net loss of $2.387 million, reflecting operational restructuring and gains from subsidiary deconsolidation. Management plans to diversify its portfolio through further acquisitions while exploring strategic alternatives to address current financial constraints.GlobeNewswireBio Green Med Solution Reports Third Quarter Financial Results and Provides Business UpdateBio Green Med Solution, Inc. announced its third quarter financial results and business updates, including a reverse stock split, share exchange agreement, asset sale, and dividend declaration. The company's operations shifted from biopharmaceuticals to fire safety and distribution following a 2025 acquisition of Fitters Sdn. Bhd. and other financial activities.BioSpaceCyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred StockCyclacel Pharmaceuticals announced a private placement of convertible Series F Preferred Stock, raising $3 million before expenses. The offering included warrants to purchase common stock at $0.51, $0.60, and $0.68 per share, expiring five years later. Net proceeds will fund working capital and extend cash runway into Q3 2025.